Introduction
Magnetic drug targeting describes the selective targeting of therapeutics bound to magnetic nanoparticles and carriers in a tissue or a region in the body, e. g. in a tumor, by magnetic fields. Therefore, magnetic particles should be able to deliver significant amounts of the bounded drugs to the tumor site. Considering this, a new concept of placing an array of permanent magnets and coils inside hollow organs of the body was developed. This gives the possibility to target endoluminal tumors (e. g. prostate carcinoma, esophagus adenocarcinoma or bile duct Klatskin tumors) which allow the minimally invasive endoscopic insertion of permanent magnets and coils very close to the tumor site.
Methods
A novel targeting model using FEM simulations of magnetic nanoparticles in blood flow under the influence of a magnetic field was designed. The targeting model describes the interaction of an external magnetic field with blood flow containing homogeneously suspended SPIOs with a certain mass fraction (SPIOs' concentration). Furthermore, biophysical models of the prostate gland, esophagus and bile duct were built and different magnetic field configurations of permanent magnets as well as coils were simulated in order to find the best setup for a high targeting efficiency. First simulation results were already applied and validated in animal trials with pigs.
Results
The simulations show that for the same concentration of nanoparticles, different settings of a single magnet lead to different velocity changes in the range of 2 % to 10 % of the maximum velocity and that below a SPIOs concentration of 3.3 % no considerable targeting effect can be achieved. Furthermore, the measurements of tissues' magnetic behaviors after application of the optimized targeting setups in pig experiments confirmed the accumulation of SPIOs at the target site.
Conclusion
This novel magnetic drug targeting model shows an improvement of the delivery rate for drug targeting systems in endoluminal tumors using optimized magnetic fields.
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